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Abstract
Background Over the last decade, multiple chemothera-
pies/targeted biologics have been approved for metastatic
colorectal cancer (mCRC). However, evidence is limited
with regards to the array of treatments received by mCRC
patients.
Objective This study examines treatment sequences (first-
to third-line chemotherapy/targeted biologics) and the
factors associated with first-line targeted biologics and
common treatment sequences for elderly mCRC patients
treated in a community setting.
Methods A retrospective cohort study was conducted in
mCRC patients diagnosed from January 2004 through
December 2009 using the Surveillance, Epidemiology and
End Results Medicare-linked database. The treatment
sequences administered to elderly mCRC patients were
empirically identified.
Results Of 4418 mCRC patients who received treatment,
1370 (31 %) received first, second, and third line; 1164
(26 %) received first and second line; and 1884 (43 %)
received only first line. The most common first line of
treatment for mCRC patients was 5-fluorouracil/leucov-
orin ? oxaliplatin (FOLFOX) ? bevacizumab (23 %) and
FOLFOX (23 %). 5-fluorouracil/leucovorin ? irinotecan
(FOLFIRI)-based regimens were commonly (22 %)
administered in second line. The most common treatment
sequence was first-line oxaliplatin or irinotecan followed by
second-line oxaliplatin or irinotecan ? bevacizumab fol-
lowed by a third-line targeted biologic. Of patients who
received first-line therapy, 47 % also received a targeted
biologic, and the factors associated were age, comorbidity
score, cancer site, geographic location, and year of diagnosis.
Conclusion Elderly mCRC patients receive a multitude
of treatments in various sequences. Further exploration of
the comparative effectiveness of treatment sequences may
yield important information for improving mCRC survival.
Key Points
Elderly metastatic colorectal cancer patients received
treatment sequences with multiple drugs
administered across various lines of treatment.
Oxaliplatin- or irinotecan-based regimens were the
most common chemotherapies, bevacizumab was the
most common targeted biologic, and the most
common treatment sequence was first-line
oxaliplatin or irinotecan followed by second-line
oxaliplatin or irinotecan ? bevacizumab followed
by a third-line targeted biologic.
Future research evaluating the comparative
effectiveness and cost effectiveness of treatment
lines and sequences for elderly patients with
metastatic colorectal cancer should be conducted.
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1 Introduction
Colorectal cancer (CRC) currently ranks third among the
most common cancers and cancer deaths in the USA [1–3].
It is estimated there will be about 132,700 new cases of
CRC and nearly 49,700 deaths because of CRC in 2015 in
the USA [1, 3]. A majority of cases (60 %) and deaths
(70 %) occur in those aged C65 years. For males between
the ages of 40 and 79 years and females aged C80 years,
CRC is the second leading cause of death [3]. As compared
with younger CRC patients, elderly CRC patients have a
lower survival rate primarily because of the stage at diag-
nosis. Moreover, the management of the disease among
elderly patients is also poor. Overall, one in four patients
has the metastatic form of the disease at diagnosis, and
nearly half of CRC patients may develop metastasis during
progression of the disease. Metastatic colorectal cancer
(mCRC) has a poor prognosis, with an overall survival rate
of 5–13 % at 5 years [4, 5], and the cost of treating
metastatic disease is twice as high as the cost of cases
without metastasis [6].
Until 2004, 5-Fluorouracil, leucovorin (5-FU/LV) had
been the standard therapy for mCRC patients, with an
estimated median overall survival of 10–14 months.
Oxaliplatin and irinotecan in combination with 5-FU/LV,
i.e., FOLFOX (5-FU/LV ? oxaliplatin) and FOLFIRI (5-
FU/LV ? irinotecan), respectively, have been commonly
prescribed to mCRC patients since 2004 [7]. Targeted
biologics such as bevacizumab and cetuximab were
approved for treating mCRC patients in 2004, which was
followed by the approval of panitumumab in 2006. These
clinically proven therapies are current standard treatments
that can be administered either as monotherapy or as a
combination to form a treatment line. With an array of
chemotherapy/targeted therapy options available for
mCRC patients, multiple lines of treatment could be
administered to a patient as needed during the course of
their treatment and thereby form a treatment sequence,
where each sequence comprises multiple lines of treat-
ments [7–9]. Currently, there is a lack of standard sequence
of chemotherapy and targeted biologics recommended for
mCRC patients [8–13]. In the absence of evidence-based
guidelines for sequencing therapy, the decision regarding
first-line treatment has been generally based on patient
factors and preferences while subsequent treatments (after
progression) are based on the treatment previously received
[14].
Recommendations have been made for healthy elderly
patients to be treated with chemotherapy and targeted
biologic combinations similar to those administered to
younger patients [15]. Specifically, irinotecan (e.g., FOL-
FIRI)- or oxaliplatin (e.g. FOLFOX)-based regimens with
or without bevacizumab for first- and second-line treatment
may be the treatment of choice [16–18]. No specific rec-
ommendations have been made for the third line of treat-
ment, but targeted biologics have been used in one study
and are currently being evaluated in ongoing clinical trials
[11, 19, 20]. Although multiple treatment options may be
available for mCRC patients, elderly patients have been
observed to frequently receive suboptimal treatment, and
only a subgroup of elderly patients may receive exhaustive
treatment management similar to that received by younger
patients [21–25]. Thus, an understanding of the demo-
graphic and clinical factors associated with various treat-
ments received by elderly mCRC patients is essential.
Moreover, evidence is limited on the current usage of
treatment sequences among elderly mCRC patients treated
in a non-experimental (community-based) setting, espe-
cially with regards to targeted biologics; assessing real-
world utilization of treatment sequences may guide in
optimizing the adequate sequential use of targeted bio-
logics in routine practice and in-turn judicious use of
healthcare resources. Thus, the objective of the study was
to describe treatment sequences (first- to third-line
chemotherapy and targeted biologics) and the factors
associated with the receipt of targeted biologics at first-line




The National Cancer Institute governs the Surveillance,
Epidemiology and End Results (SEER) program under
which participating regions provide cancer registry data
that includes information on patient demographics, socio-
economic variables, stage at diagnosis, tumor site, tumor
characteristics, and initial treatment after diagnosis. After
the expansion of the SEER program in 2000, the 16 par-
ticipating registries (i.e., San Francisco/Oakland, Detroit,
Seattle, Atlanta, Rural Georgia, Los Angeles, San Jose-
Monterey area, Greater California, Connecticut, Iowa, New
Mexico, Utah, Hawaii, Kentucky, Louisiana, and New
Jersey) represent nearly 28 % of the US population, and
SEER records 98 % of the cancer-diagnosed cases in these
regions [26, 27]. These data have been used for numerous
cancer epidemiology and chemotherapy utilization studies;
validity and completeness of the database has also been
shown in previous studies [28–30]. The SEER-Medicare
data linked cancer patients aged C65 years from the SEER
program to their administrative claims from the Medicare
program, which insures individuals aged[65 years in the
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USA [26]. Medicare data includes healthcare utilization
information for inpatient, outpatient, professional (provi-
der), skilled nursing facility, hospice, and devices and
medical equipment.
2.2 Study Population
Patients diagnosed with mCRC at C65 years from January
2004 to December 2009 were included. Targeted therapies
such as bevacizumab and cetuximab became available for
mCRC patients in 2004; hence, analysis was restricted to
patients diagnosed after 2004. We used an American Joint
Cancer Committee (AJCC) criterion to characterize meta-
static disease, and patientswithAJCC stage IVwere included.
Patients who were ascertained as mCRC through autopsy/
death certificate were excluded, as patients had already died
before receiving any treatment.Also, patientswho diedwithin
30 days of diagnosis were excluded as they were unlikely to
have received treatment sequences [14, 31, 32]. For the
completeness of information on treatment sequences in
Medicare claims, patients were required to be enrolled in both
Medicare parts A and B without any Health Maintenance
Organization (HMO) enrollment from the time of diagnosis to
death or end of study. Similar inclusion/exclusion criteria
have been used in previous studies [31, 33–36].
2.3 Treatment Identification
We identified systemic chemotherapy and targeted bio-
logics currently approved by the US FDA for treatment of
mCRC patients and recommended by the National Com-
prehensive Cancer Network [7–9], i.e., 5-florouracil,
irinotecan, oxaliplatin, bevacizumab, cetuximab, and pan-
itumumab. Aflibercept, although approved in 2012, was not
included in this study, as Medicare claims were only
available until 2010. Chemotherapeutic and targeted bio-
logics agents could be given either as monotherapy or as a
combination therapy to form a ‘line of treatment’. We
identified the first three lines of treatment administered to
mCRC patients and used Healthcare Common Procedural
Coding System (HCPCS) codes from the Medicare out-
patient and physician files to identify chemotherapy or
targeted biologics. HCPCS codes used were 5-florouracil—
J9190; irinotecan—J9206; leucovorin—J0640, J0641;
oxaliplatin—J9263, C9205; bevacizumab—J9035, C9214,
S0116; cetuximab—J9055, C9215, and panitumumab—
J9303, C9235.
2.4 Line and Sequence Identification
Adata-driven ‘line of treatment’ approachwas used to identify
the treatment sequences. Start of a line of treatment was
determined based on the date of the first claim for the drug.
Additionally, for the drug to be considered as a line of treat-
ment, it was required to be re-administered within 35 days
(28 ? 7 additional days). A combination regimen was defined
when an additional drugwas administeredwithin 28days of the
first drug claim and was re-administered within 35 days
(28 ? 7additional days).Endof a lineof treatmentwasdefined
as (1) a line continues until the end of the study; (2) no drug is
administeredwithin 90 days, or (3) a previous line of treatment
is interrupted by a new line of treatment [37]. This process was
conducted three times to identify three treatment lines. Similar
methodology has been used by previous treatment pattern
studies [11, 38, 39]. For patients receiving at least two lines of
treatments, first- to third-line treatments were combined to
define treatment sequences. Finally, we only included patients
for whom the gap between treatment lines (first to second line
and second to third line) was less than 1 year.
2.5 Patient and Tumor Characteristics
SEER data records demographic information such as age,
race, sex, marital status, year of diagnosis, and geographic
location at the time of diagnosis. The variable ‘‘percent below
poverty line at zip code level’’ obtained from the US Census
Data was used as a proxy for patient’s socio-economic (pov-
erty) status. The poverty variable was then categorized into
quartiles to differentiate individuals living in areaswith higher
versus lower rates of poverty. Tumor stage, grade and site of
cancer (i.e., colon or rectal) were obtained from SEER data.
A Charlson Comorbidity Index (CCI) was computed with
inpatient, outpatient, and physician claims from1 year prior to
themonth of diagnosis using non-cancer comorbid conditions
initially identified by Charlson et al. [40–42] to affect overall
morbidity andmortality. Metastases type was identified using
inpatient, outpatient, and physician claims within 3 months
after diagnosis based on the algorithm used by Chawla et al.
[43]. International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes were used to iden-
tify metastases [Table 1 in the Electronic Supplementary
Marerial (ESM)], and patients were considered to have
metastases if they had at least one inpatient claim or two
outpatient/provider claims on separate days [29, 43, 44].
2.6 Statistical Analyses
Descriptive statistics (mean, standard deviation, and med-
ian time) for each of the treatments (monotherapy or
combination) in first, second, and third line, as well as
treatment sequences, were calculated. We computed
descriptive statistics for patients receiving targeted bio-
logics at first line, and used a logistic regression analysis to
assess factors associated with the receipt of targeted bio-
logics in first line. Factors associated with the receipt of
commonly administered targeted biologics-based treatment
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sequences were assessed using univariate chi-squared
statistic and multinomial logistic regression. In contrast to
conventional logistic regression, multinomial logistic
regression allowed the use of dependent variables with
more than two categories and thereby enabled us to
examine any association between multiple treatment
sequences and patient/tumor characteristics [45–47]. All
analyses were conducted using SAS version 9.3, and sta-
tistical significance was determined at a = 0.05.
3 Results
Of the 9819 patients diagnosed with mCRC from January
2004 to December 2009 who met other inclusion criteria
(Fig. 1 in the ESM); 5192 (53 %) did not receive treat-
ment, 4418 (45 %) received treatment, and 209 (2 %) were
excluded, as the gap between first to second line or second
to third line was more than 1 year. The baseline charac-
teristics for all mCRC patients and patients who received
treatment are shown in Table 1. Overall, the sample com-
prised 81 % Caucasians, 52 % females, 83 % living in a
metropolitan area, 77 % with metastatic colon cancer, and
23 % with metastatic rectal cancer (Table 1). A majority of
patients had a liver metastasis (63 %), followed by abdo-
men (20 %) and lung (17 %). We were not able to identify
the type of metastases in 20 % of patients (Table 1) even
though they were indicated as metastatic (AJCC stage IV)
in SEER. Patients who received treatment were mostly
diagnosed before the age of 80 years (80 %) and had a
comorbidity score of 0 or 1 (82 %).
3.1 Treatment Lines and Sequences
Of the 4418 patients who received treatment, 1370 (31 %)
received first-, second-, and third-line treatment, 1164 (26 %)
received first and second-line treatment, and 1884 (43 %)
received only first-line treatment. Table 2 shows the top ten
Table 1 Characteristics of metastatic colorectal cancer patients and
patients





therapy (n = 4418)
Age (years)
65–69 2098 (21.4) 1333 (30.2)
70–74 2092 (21.3) 1190 (26.9)
75–79 2083 (21.2) 1022 (23.1)
80–84 1851 (18.9) 627 (14.2)
C85 1695 (17.3) 246 (5.6)
Race/ethnicity
Caucasians 7924 (80.7) 3693 (83.6)
African Americans 1095 (11.2) 382 (8.7)
Other 800 (8.2) 343 (7.8)
Sex
Male 4720 (48.1) 2318 (52.5)
Female 5099 (51.9) 2100 (47.5)
Marital status
Married 4714 (48.0) 2571 (58.2)
Unmarried 4769 (48.6) 1718 (38.9)
Unknown 336 (3.4) 129 (2.9)
Tumor grade
Well/moderately differentiated 5112 (52.1) 2554 (57.8)
Poorly/undifferentiated 2438 (24.8) 1148 (26.0)
Unknown 2269 (23.1) 716 (16.2)
Comorbidity scores
0 4712 (48.0) 2357 (53.4)
1 2677 (27.3) 1280 (29.0)
2 1227 (12.5) 430 (9.7)
C3 1203 (12.3) 351 (7.9)
Metastasis
Liver 6234 (63.5) 2969 (67.2)
Lung 1692 (17.2) 730 (16.5)
Abdomen 1953 (19.9) 873 (19.8)
Other 1618 (16.5) 696 (15.8)
Unknown 1969 (20.1) 747 (16.9)
Cancer site
Colon 7559 (77.0) 3276 (74.2)
Rectal 2260 (23.0) 1142 (25.9)
SES (poverty)
1st (low SES) 2454 (25.0) 989 (22.4)
2nd 2404 (24.5) 1070 (24.2)
3rd 2502 (25.5) 1139 (25.8)
4th (high SES) 2459 (25.0) 1220 (27.6)
Region
Midwest 1284 (13.1) 566 (12.8)
North east 2212 (22.5) 1000 (22.6)
South 2275 (23.2) 1035 (23.4)
West 4048 (41.2) 1817 (41.1)
Urban/rural
Less urban/rural 1097 (11.2) 477 (10.8)
Urban 588 (6.0) 268 (6.1)
Metro 8132 (82.8) 3672 (83.1)
Table 1 continued





therapy (n = 4418)
Year of diagnosis
2004 1588 (16.2) 731 (16.6)
2005 1510 (15.4) 696 (15.8)
2006 1811 (18.4) 780 (17.7)
2007 1668 (17.0) 722 (16.3)
2008 1650 (16.8) 752 (17.0)
2009 1592 (16.2) 737 (16.7)
Data are presented as n (%)
CTX chemotherapy, mCRC metastatic colorectal cancer, pts patients, SES
socio-economic status
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treatment regimens for first-, second-, and third-line treatment,
along with duration of therapy. The most common first-line
treatments were FOLFOX (oxaliplatin based) ? beva-
cizumab (23 %), FOLFOX [oxaliplatin based (23 %)] alone
and 5-FU ? leucovorin (12 %) administered for a median
duration of 188, 124, and 97 days, respectively (Table 2). In
second-line treatment, FOLFOX (oxaliplatin based) ? beva-
cizumab (18 %) was the most common regimen, followed by
FOLFIRI (irinotecan based) ? bevacizumab (14 %) and
FOLFIRI (irinotecan based) alone (8 %). Themedian duration
for FOLFOX (oxaliplatin based) ? bevacizumab, FOLFIRI
(irinotecan based) ? bevacizumab, and FOLFIRI (irinotecan
based) alone was observed to be 156, 155, and 111 days,
respectively (Table 2). The most common regimens adminis-
tered in third-line treatment (Table 2) were cetux-
imab ? irinotecan (15 %), FOLFIRI (irinotecan based)
? bevacizumab (13 %), and FOLFOX (oxaliplatin based)
? bevacizumab (8 %).
Table 2 Treatment regimens
and duration for metastatic
colorectal cancer patients by
line of therapy
Treatment line and regimens Patients, n (%) Duration (days)
Mean SD Median
First line N = 4418
FOLFOX ? bevacizumab 1026 (23.2) 197.5 115.5 188
FOLFOX 1003 (22.7) 139.1 94.4 124
FU/LV 510 (11.5) 130.9 111.1 97
Oxaliplatin 325 (7.4) 126.9 92.3 104
FU/LV ? bevacizumab 218 (4.9) 180.2 153.2 132
Oxaliplatin ? bevacizumab 216 (4.9) 186.9 114.3 167
FOLFIRI ? bevacizumab 194 (4.4) 208.7 158.5 177
FOLFIRI 183 (4.1) 149.2 114.0 136
Bevacizumab 151 (3.4) 186.3 144.0 145
FU 150 (3.4) 84.2 57.3 67
Others 442 (10.0) 135.8 100.0 111
Second line N = 2534
FOLFOX ? bevacizumab 449 (17.7) 183.3 136.5 156
FOLFIRI ? bevacizumab 353 (13.9) 198.0 157.2 155
FOLFIRI 202 (8.0) 128.0 83.5 111
Irinotecan 192 (7.6) 126.4 93.0 97
FU/LV ? bevacizumab 175 (6.9) 181.1 143.1 139
FOLFOX 157 (6.2) 132.6 74.3 120
Cetuximab ? irinotecan 139 (5.5) 155.5 98.8 135
Oxaliplatin ? bevacizumab 127 (5.0) 164.3 113.9 128
Bevacizumab 116 (4.6) 194.1 207.3 133
FU/LV 98 (3.9) 144.9 128.8 118
Others 526 (20.8) 138.3 104.7 117
Third line N = 1370
Cetuximab ? irinotecan 207 (15.1) 152.0 124.7 125
FOLFIRI ? bevacizumab 184 (13.4) 195.0 158.8 153
FOLFOX ? bevacizumab 104 (7.6) 162.1 104.6 138
FOLFIRI 91 (6.6) 119.7 105.3 96
Irinotecan 82 (6.0) 123.0 89.2 89
Cetuximab 78 (5.7) 131.5 137.3 101
FU/LV ? bevacizumab 75 (5.5) 199.1 201.3 132
Bevacizumab 71 (5.2) 215.2 180.1 166
Bevacizumab ? irinotecan 57 (4.2) 167.2 109.9 134
FOLFOX 51 (3.7) 120.8 71.5 98
Others 370 (30.7) 135.9 112 110
FU 5-fluorouracil, FOLFOX 5-FU ? LV? oxaliplatin, FOLFIRI 5-FU ? LV ? irinotecan, LV leucovorin,
SD standard deviation
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Table 4 Characteristics of metastatic colorectal cancer patients receiving targeted biologic in first line and multivariable regression for factors
associated with the receipt of targeted biologics











OR (95 % CI)
Total N = 4418 N = 2077
Age (years)
65–69 1333 (30.2) 664 (49.8) Referent
70–74 1190 (26.9) 555 (46.6) 0.88 (0.74–1.04)
75–79 1022 (23.1) 451 (44.1) 0.77 (0.64–0.91)*
80–84 627 (14.2) 280 (44.7) 0.78 (0.64–0.96)*
85? 246 (5.6) 127 (51.6) 0.99 (0.74–1.33)
Race/ethnicity
Caucasians 3693 (83.6) 1732 (46.9) Referent
African Americans 382 (8.7) 181 (47.4) 0.94 (0.74–1.20)
Others 343 (7.8) 164 (47.8) 1.05 (0.82–1.34)
Sex
Male 2318 (52.5) 992 (42.8) Referent
Female 2100 (47.5) 1085 (51.7) 0.97 (0.85–1.10)
Marital status
Married 2571 (58.2) 1190 (46.3) Referent
Unmarried 1718 (38.9) 828 (48.2) 1.09 (0.96–1.25)
Unknown 129 (2.9) 59 (45.7) 1.07 (0.73–1.56)
Tumor grade
Well/moderately differentiated 2554 (57.8) 1196 (46.8) Referent
Poorly/undifferentiated 1148 (26.0) 542 (47.2) 1.04 (0.90–1.21)
Unknown 716 (16.2) 339 (47.3) 1.03 (0.86–1.23)
Comorbidity Scores
0 2357 (53.4) 1122 (47.6) Referent
1 1280 (29.0) 585 (45.7) 0.85 (0.73–0.98)*
2 430 (9.7) 211 (49.1) 1.00 (0.80–1.25)
C3 351 (7.9) 159 (45.3) 0.80 (0.63–1.01)
Metastasis
Liver 2969 (67.2) 1476 (49.7) 1.14 (0.93–1.38)
Lung 730 (16.5) 358 (49.0) 1.06 (0.89–1.26)
Abdomen 873 (19.8) 423 (48.5) 1.00 (0.83–1.20)
Other 696 (15.8) 304 (43.7) 0.77 (0.64–0.92)*
Unknown 747 (16.9) 283 (37.9) 0.68 (0.52–0.88)*
Cancer site
Colon 3276 (74.2) 1618 (49.4) Referent
Rectal 1142 (25.9) 459 (40.2) 0.69 (0.59–0.80)*
SES (poverty)
1st (low SES) 989 (22.4) 457 (46.2) Referent
2nd 1070 (24.2) 504 (47.1) 1.07 (0.89–1.29)
3rd 1139 (25.8) 549 (48.2) 1.13 (0.93–1.37)
4th (high SES) 1220 (27.6) 567 (46.5) 1.10 (0.89–1.35)
Region
Midwest 566 (12.8) 247 (43.6) Referent
North east 1000 (22.6) 443 (44.3) 0.95 (0.76–1.20)
South 1035 (23.4) 533 (51.5) 1.31 (1.05–1.64)*
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Treatment sequences administered to patients, along
with durations, are shown in Table 3. The most common
treatment sequence was first-line oxaliplatin or irinotecan
followed by second-line oxaliplatin or irinotecan ? beva-
cizumab followed by a third-line targeted biologic (OI-
OIB-TB). This sequence was given to nearly 11 % of
patients, with a median of 86 days first-line, 160 days
second-line, and 146 days third-line treatment (Table 3).
The second most common sequence (8 %) was first-line
oxaliplatin or irinotecan ? bevacizumab (median 195
days) followed by second-line oxaliplatin or irinote-
can ? bevacizumab (median 143 days) followed by a
third-line targeted biologic (median 132 days; OIB-OIB-
TB). Other common sequences (Table 3) received by
patients were first-line oxaliplatin or irinotecan followed by
second-line oxaliplatin or irinotecan ? bevacizumab (OI-
OIB) and first-line oxaliplatin or irinotecan ? beva-
cizumab followed by second-line oxaliplatin or irinote-
can ? bevacizumab (OIB-OIB). For sequences OI-OIB
and OIB-OIB, no third-line treatment was observed.
Sequences with bevacizumab in first line were observed to
be administered for a relatively longer duration of time
than sequences without bevacizumab in first line (Table 3).
3.2 Factors Associated with Receipt of Targeted
Biologic and Treatment Sequences
Characteristics of patients receiving targeted biologics at
first-line therapy, along with logistic regression results, are
shown in Table 4. Of patients who received first-line
therapy, 47 % also received a targeted biologic (Table 4).
As compared with patients aged 65–69 years, patients aged
75–79 or 80–84 years were less likely to receive targeted
biologics (Table 4). Patients with a comorbidity score of 1
and with metastatic rectal cancer were also less likely to
receive a targeted biologic at first line. Patients residing in
the South as well as in metropolitan areas were relatively
more likely to receive targeted biologics and, as expected,
utilization of targeted biologics was higher among patients
diagnosed in the years 2005–2009 than among those
diagnosed in 2004 (Table 4).
Table 5 shows the univariate comparison of character-
istics of patients who received the commonly administered
targeted biologic-based treatment sequences using the chi-
squared statistic. In the univariate analysis between treat-
ment sequences, statistically significant differences were
only observed with regards to comorbidity score, other
metastasis, and year of diagnosis (Table 5). Factors asso-
ciated with commonly administered treatment sequences,
assessed using multinomial logistic regression with treat-
ment sequence (four categories) as the dependent variable
and OI-OIB as the reference category, are presented in
Table 6. Patients aged 75–79 years were significantly less
likely to receive three-line treatment sequences, i.e., OIB-
OIB-TB and OI-OIB-TB, than an OI-OIB treatment
sequence (Table 6). Female mCRC patients were observed
to be 0.37 times less likely to receive an OIB-OIB-TB
treatment sequence, and patients with a comorbidity score
of 1 (vs. 0) were less likely to receive OIB-OIB-TB, OI-
OIB-TB, and OIB-OIB treatment sequences (Table 6).
Table 4 continued











OR (95 % CI)
West 2969 (67.2) 854 (47.0) 1.06 (0.86–1.32)
Urban/rural
Less urban/rural 477 (10.8) 210 (44.0) Referent
Urban 268 (6.1) 126 (47.0) 1.24 (0.90–1.71)
Metro 3672 (83.1) 1741 (47.4) 1.29 (1.03–1.61)*
Year of diagnosis
2004 731 (16.6) 112 (15.3) Referent
2005 696 (15.8) 368 (52.9) 6.55 (5.09–8.44)*
2006 780 (17.7) 447 (57.3) 7.62 (5.93–9.78)*
2007 722 (16.3) 391 (54.2) 6.70 (5.20–8.62)*
2008 752 (17.0) 376 (50.0) 5.80 (4.51–7.45)*
2009 737 (16.7) 383 (52.0) 6.21 (4.83–7.98)*
CI confidence interval, mCRC metastatic colorectal cancer, OR odds ratio, SES socio-economic status
* Significant at a = 0.05
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Table 5 Characteristics of metastatic colorectal cancer patients by commonly administered treatment sequences
Characteristics Treatment sequences
OI-OIB-TB (N = 275) OIB-OIB-TB (N = 199) OI-OIB (N = 178) OIB-OIB (N = 169) P value
Age (years) 0.0600
65–69 108 (39.3) 81 (40.7) 56 (31.5) 56 (33.1)
70–74 84 (30.6) 72 (36.2) 57 (32.0) 49 (29.0)
75–79 56 (20.4) 32 (16.1) 47 (26.4) 38 (22.5)
C80 27 (9.8) 14 (7.0) 18 (10.1) 26 (15.4)
Race/ethnicity 0.4093
Caucasian 235 (85.5) 173 (86.9) 144 (80.9) 142 (84.0)
Other 40 (14.6) 26 (13.1) 34 (19.1) 27 (16.0)
Sex 0.1751
Male 161 (58.6) 113 (56.8) 86 (48.3) 91 (53.9)
Female 114 (41.5) 86 (43.2) 92 (51.7) 78 (46.2)
Marital status 0.2983
Married 189 (68.7) 125 (62.8) 114 (64.0) 102 (60.4)
Unmarried/unknown 86 (31.3) 74 (37.2) 64 (36.0) 67 (39.6)
Tumor grade 0.7064
Well/moderately differentiated 176 (64.0) 121 (60.8) 105 (59.0) 107 (63.3)
Poorly/undifferentiated/unknown 99 (36.0) 78 (39.2) 73 (41.0) 62 (36.7)
Comorbidity scores 0.0129*
0 173 (62.9) 123 (61.8) 84 (47.2) 97 (57.4)
1 71 (25.8) 49 (24.6) 69 (38.8) 44 (26.0)
C2 31 (11.3) 27 (13.6) 25 (14.0) 28 (16.6)
Metastasis
Liver 206 (74.9) 143 (71.9) 126 (70.8) 128 (75.7) 0.6458
Lung 41 (14.9) 31 (15.6) 22 (12.4) 26 (15.4) 0.8079
Abdomen 57 (20.7) 37 (18.6) 31 (17.4) 25 (14.8) 0.4608
Other 43 (15.6) 19 (9.6) 34 (19.1) 18 (10.7) 0.0248*
Unknown 37 (13.5) 29 (14.6) 31 (17.4) 24 (14.2) 0.7010
Cancer site 0.0829
Colon 194 (70.6) 155 (77.9) 128 (71.9) 135 (79.9)
Rectal 81 (29.5) 44 (22.1) 50 (28.1) 34 (20.1)
SES (poverty) 0.2732
1st (low SES) 62 (22.6) 41 (20.6) 34 (19.1) 41 (24.3)
2nd 56 (20.4) 53 (26.6) 48 (27.0) 37 (21.9)
3rd 69 (25.1) 53 (26.6) 43 (24.2) 54 (32.0)
4th (high SES) 88 (32.0) 52 (26.1) 53 (29.8) 37 (21.9)
Region 0.0915
Midwest 31 (11.3) 18 (9.1) 20 (11.2) 15 (8.9)
North east 55 (20.0) 41 (20.6) 38 (21.4) 36 (21.3)
South 45 (16.4) 45 (22.6) 49 (27.5) 48 (28.4)
West 144 (52.4) 95 (47.7) 71 (39.9) 70 (41.4)
Urban/rural 0.1894
Less urban/rural 22 (8.0) 18 (9.1) 19 (10.7) 24 (14.2)
Metro/urban 253 (92.0) 181 (91.0) 159 (89.3) 145 (85.8)
Year of diagnosis \0.0001*
2004–2005 109 (39.6) 52 (26.1) 56 (31.5) 40 (23.7)
2006–2007 90 (32.7) 95 (47.7) 48 (27.0) 56 (33.1)
2008–2009 76 (27.6) 52 (26.1) 74 (41.6) 73 (43.2)
Data are presented as n (%) unless otherwise indicated
OI-OIB first-line oxaliplatin or irinotecan followed by second-line oxaliplatin or irinotecan ? bevacizumab, OIB-OIB first-line oxaliplatin or irinote-
can ? bevacizumab followed by second-line oxaliplatin or irinotecan ? bevacizumab, OI-OIB-TB OI-OIB followed by a third-line targeted biologic,
OIB-OIB-TB OIB-OIB followed by a third-line targeted biologic, SES socio-economic status
* Significant at a = 0.05
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Table 6 Multinomial logistic
regression for factors associated
with receipt of commonly
administered treatment
sequences
Factors OI-OIB-TB OIB-OIB-TB OIB-OIB
Age (years)
65–69 Referent Referent Referent
70–74 0.87 (0.52–1.45) 0.77 (0.47–1.25) 0.89 (0.52–1.54)
75–79 0.43 (0.24–0.77)* 0.59 (0.35–1.00)* 0.78 (0.43–1.41)
80? 0.45 (0.20–1.01) 0.73 (0.36–1.50) 1.36 (0.65–2.85)
Race/ethnicity
Caucasian Referent Referent Referent
Other 0.54 (0.29–1.00) 0.63 (0.37–1.10) 0.74 (0.41–1.36)
Sex
Male Referent Referent Referent
Female 0.63 (0.41–0.99)* 0.67 (0.44 – 1.00) 0.76 (0.48–1.19)
Marital status
Married Referent Referent Referent
Unmarried/unknown 1.29 (0.81–2.05) 0.94 (0.61–1.45) 1.29 (0.81–2.06)
Tumor grade
Well/moderately differentiated Referent Referent Referent
Poorly/undifferentiated/unknown 0.94 (0.6–1.46) 0.83 (0.55–1.26) 0.91 (0.57–1.44)
Comorbidity scores
0 Referent Referent Referent
1 0.45 (0.28–0.72)* 0.52 (0.34–0.81)* 0.51 (0.31–0.84)*
C2 0.61 (0.32–1.18) 0.57 (0.31–1.06) 0.92 (0.48–1.74)
Metastasis (yes vs. no)
Liver 0.77 (0.36–1.66) 1.16 (0.58–2.36) 1.00 (0.45–2.25)
Lung 1.36 (0.72–2.57) 1.21 (0.67–2.18) 1.38 (0.72–2.65)
Abdomen 1.03 (0.53–1.98) 1.28 (0.71–2.30) 0.84 (0.43–1.67)
Other 0.39 (0.20–0.75)* 0.83 (0.47–1.44) 0.50 (0.26–0.98)*
Unknown 0.56 (0.21–1.47) 0.87 (0.36–2.15) 0.65 (0.23–1.80)
Cancer site
Colon Referent Referent Referent
Rectal 0.62 (0.38–1.03) 1.01 (0.65–1.59) 0.59 (0.35–1.00)*
SES (poverty)
1st (low SES) Referent Referent Referent
2nd 0.92 (0.48–1.77) 0.55 (0.30–1.02) 0.70 (0.36–1.37)
3rd 0.88 (0.44–1.76) 0.65 (0.35–1.23) 1.09 (0.55–2.16)
4th (high SES) 0.69 (0.34–1.41) 0.69 (0.36–1.31) 0.58 (0.28–1.21)
Region
Midwest Referent Referent Referent
North east 1.38 (0.60–3.19) 0.87 (0.41–1.84) 1.59 (0.66–3.79)
South 0.88 (0.39–2.02) 0.51 (0.24–1.07) 1.22 (0.53–2.84)
West 1.43 (0.66–3.10) 1.17 (0.59–2.32) 1.37 (0.61–3.09)
Urban/rural
Less urban/rural Referent Referent Referent
Metro/urban 1.25 (0.57–2.74) 1.25 (0.59–2.61) 0.76 (0.36–1.62)
Year of diagnosis
2004–2005 Referent Referent Referent
2006–2007 2.55 (1.48–4.40) 1.17 (0.71–1.93) 1.75 (0.97–3.14)
2008–2009 0.84 (0.49–1.45) 0.59 (0.36–0.94)* 1.50 (0.87–2.57)
Data are presented as odds ratio (95 % confidence interval)
OIB-OIB first-line oxaliplatin or irinotecan ? bevacizumab followed by second-line oxaliplatin or irinote-
can ? bevacizumab, OI-OIB-TB OI-OIB followed by a third-line targeted biologic, OIB-OIB-TB OIB-OIB fol-
lowed by a third-line targeted biologic, SES socio-economic status
* Significant at a = 0.05
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Metastatic rectal cancer patients were also less likely to
receive an OIB-OIB treatment sequence.
4 Discussion
Important advances in treatments for mCRC patients over
the last decade have provided clinicians with a multitude of
treatment options. The addition of oxaliplatin or irinotecan
to 5-FU/LV increased the median survival up to 19.5
months as compared with 14.8 months with 5-FU/LV alone
[48, 49]. Moreover, the availability of targeted biologics
such as bevacizumab has been found to increase the overall
survival to as high as 25.5 months [50]. Thus, irinotecan- or
oxaliplatin-based chemotherapy regimens have been rec-
ommended, and the addition of bevacizumab has been
considered a reasonable option [16, 17]. Sequencing of
these chemotherapies and targeted biologics is equally
important, as treatments received during the first few
months of the diagnosis are critical [7, 51, 52], but correct
sequencing of treatments could be challenging, and evi-
dence of current utilization patterns may be informative
[16, 17]. We used community-based SEER-Medicare
linked data to identify the treatment patterns, sequences,
and associated factors for mCRC patients diagnosed from
2004 to 2009.
FOLFOX- or oxaliplatin-based regimens were most
frequently administered to mCRC patients as their first-line
treatment, which is consistent with previous findings
among relatively younger patients [6, 11, 38]. Bikov et al.
[53] found 5-FU-based treatment to be the most common
therapy and oxaliplatin-based therapy as the second most
common treatment; however, their analyses only included
elderly metastatic colon cancer patients diagnosed until
2007 [53], and prescribing patterns may have changed in
the subsequent years. The observation that FOLFOX- or
oxaliplatin-based regimens are preferred as first-line treat-
ment is consistent with their relatively better toxicity pro-
file as compared with FOLFIRI- or irinotecan-based
regimens [50, 54, 55]. However, a recent systematic review
concluded that first-line oxaliplatin- or irinotecan-based
regimens are equally efficacious for mCRC patients [16],
and the efficacy and safety of these treatments for elderly
patients has been found to be comparable to that in younger
patients [15]. Nearly half of the patients had a targeted
biologic as a part of their first-line treatment, with a sig-
nificant increase in patients receiving a targeted biologic in
the last decade as shown by the results of our study and that
by Abrams et al. [38]. As the evidence supporting the
survival benefit of targeted biologics for elderly patients
becomes more widespread, elderly mCRC patients may
often receive targeted biologics during first-line treatment.
Alternatively, we also found that patients in older age
groups, 75–79 and 80–84 years, and patients with higher
comorbidity scores had a lower likelihood of receiving a
targeted biologic in first line, which reflects concerns with
regards to prevalence of more comorbidities, cardiovas-
cular, and cerebrovascular toxicities, and less access to
specialist care in these older patients [14, 56, 57].
Consistent with previous findings, FOLFIRI- or
irinotecan-based regimens were relatively more common in
second-line treatment, and cetuximab ? irinotecan was the
most common regimen at the third line [11, 53]. Treatment
sequencing showed mCRC patients receiving treatments
(first to third line) in various sequences. The two most
common sequences consisted of patients receiving three
lines of treatment, with the difference being the receipt of
bevacizumab in the first line. Bevacizumab was commonly
observed to be administered as second-line treatment in
combination with chemotherapy among patients who had
previously been treated with bevacizumab in the first line.
Previous studies by Abrams et al. [38] and Hess et al. [11]
found similar results, but treatment with bevacizumab in
second line following progression with bevacizumab in
first line was not recommended during the time of the
study. However, based on some recent studies, it has now
been included in the National Comprehensive Cancer
Network guidelines [58–60]. Our results show that mCRC
patients receive treatments in sequences that may not
necessarily be recommended or clinically shown to have
survival benefit. While clinical trials [19, 20] are underway
to definitively examine the comparative efficacy of dif-
ferent treatment sequences, comparative-effectiveness
studies using community-level data may provide evidence
to better inform clinicians. Additionally, as patients may
receive a treatment continuum to prolong their survival, the
overall cost to treat mCRC patients would increase con-
siderably and thereby necessitate economic evaluation of
treatment sequences.
Study results should be interpreted in light of the fol-
lowing limitations. First, identification of lines of treatment
administered was limited to the first three lines. Since,
80–90 % of mCRC patients receive a maximum of three
lines of treatment [11, 61], this limitation should not sub-
stantially reduce the applicability of our findings. Second,
only drugs that require administration by a healthcare
provider were considered for our analysis, and orally
administered drugs (e.g., capecitabine) were not included
because Medicare part D data were not available. A pre-
vious study by Hess et al. [11] found that capecitabine was
administered to 8.9 % at first line, 4.9 % at second line,
and 6.9 % at third line. Third, we only included patients
with a gap between treatment lines of less than 1 year.
However, additional analyses including these patients
showed results similar to our primary analyses (Tables 2
and 3 in the ESM). Fourth, the factors assessed were
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limited to patient and tumor characteristics available from
the SEER-Medicare dataset and did not include patient or
physician preferences, which are known to influence
treatment receipt. Finally, findings of the study are only
generalizable to mCRC patients aged C65 years who are
not enrolled in Medicare Part C plans.
5 Conclusion
Based on the study results, we observed that elderly mCRC
patients receive a treatment continuum with multiple drugs
administered across various lines of treatment. As recom-
mended and similar to studies in younger populations,
oxaliplatin- or irinotecan-based regimens were the most
common chemotherapies, with bevacizumab the most
common targeted biologic administered. Treatment
sequencing studies using real-world data among overall
and elderly mCRC populations are limited, and future
studies should evaluate the utilization of treatment
sequences using other national data sources. Additionally,
studies assessing the comparative and cost effectiveness of
the most common treatment sequences identified should be
conducted to provide evidence-based recommendations for
clinicians and policy makers.
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